SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives $10.00 Average PT from Analysts

Shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS) have received an average rating of “Moderate Buy” from the six ratings firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, four have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $10.00.

A number of equities analysts have recently weighed in on SABS shares. Chardan Capital reiterated a “buy” rating and set a $12.00 price target on shares of SAB Biotherapeutics in a report on Thursday, December 18th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of SAB Biotherapeutics in a research note on Monday, December 29th. Wall Street Zen upgraded shares of SAB Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 22nd. UBS Group started coverage on shares of SAB Biotherapeutics in a report on Wednesday, January 7th. They issued a “buy” rating and a $7.00 price objective on the stock. Finally, Guggenheim initiated coverage on shares of SAB Biotherapeutics in a report on Friday, December 19th. They issued a “buy” rating and a $15.00 target price for the company.

Institutional Investors Weigh In On SAB Biotherapeutics

Several institutional investors and hedge funds have recently modified their holdings of SABS. State of Wyoming acquired a new position in SAB Biotherapeutics during the 4th quarter worth about $34,000. ADAR1 Capital Management LLC lifted its position in shares of SAB Biotherapeutics by 75.6% during the fourth quarter. ADAR1 Capital Management LLC now owns 26,344 shares of the company’s stock worth $99,000 after purchasing an additional 11,344 shares in the last quarter. State Street Corp acquired a new stake in shares of SAB Biotherapeutics during the fourth quarter worth about $49,000. Fifth Lane Capital LP purchased a new position in shares of SAB Biotherapeutics in the fourth quarter valued at approximately $56,000. Finally, Dimensional Fund Advisors LP acquired a new position in shares of SAB Biotherapeutics in the third quarter valued at approximately $32,000. Hedge funds and other institutional investors own 7.82% of the company’s stock.

SAB Biotherapeutics Stock Down 5.8%

Shares of NASDAQ SABS opened at $3.57 on Tuesday. The company has a market capitalization of $169.97 million, a P/E ratio of -1.16 and a beta of 0.59. The company has a debt-to-equity ratio of 0.02, a current ratio of 10.49 and a quick ratio of 10.50. The company has a 50 day simple moving average of $3.97 and a 200-day simple moving average of $3.17. SAB Biotherapeutics has a 1 year low of $1.00 and a 1 year high of $6.60.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.